Second-Line Therapies in Metastatic Urothelial Carcinoma

作者：Narayanan Sujata; Harshman Lauren C; Srinivas Sandy^*

来源：Hematology-Oncology Clinics of North America, 2015, 29(2): 341-+.

DOI：10.1016/j.hoc.2014.10.007

• Refractory
• Therapies in urothelial cancer
• Chemotherapy
• Targeted
• Immunotherapy

Patients with relapsed or refractory urothelial carcinoma (UC) face a poor prognosis and a dearth of available treatment options that improve their survival. End-organ function and performance status play a vital role in the choice of second-line therapies. Evidence supporting the use of cytotoxic chemotherapy, as single agents or in combination, arises from small phase 2 studies with modest responses. With the evolution of genomic testing in UC, several pathways amenable to available targeted therapies have emerged. Encouraging patient participation in clinical trials is critical to improve patient outcomes and to advance the current modest treatment armamentarium.

• 出版日期2015-4